Mayne Pharma Group (MYX) H1 2026 earnings summary

Executive summary

• Revenue for H1 FY26 was $212.1m (AUD 212.1m), down 0.5% year-over-year, with resilient earnings and disciplined margin management despite transaction-related uncertainty.

• Gross margin improved to 65.3% from 61.4% in the prior period, driven by favorable product mix, especially in Dermatology.

• Underlying EBITDA was $28.6m, down 8% year-over-year, reflecting higher investment in Women's Health and international expansion.

• Net loss after tax narrowed to $12.1m from $20.0m in the prior period, a 40% improvement.

• Leadership transition announced, with Aaron Gray appointed CEO, succeeding Shawn Patrick O'Brien, and ongoing search for CFO.

Financial highlights

• Revenue: $212.1m (down 0.5% year-over-year); Gross profit: $138.6m (up 6% year-over-year); Gross margin: 65.3% (up from 61.4%).

• Underlying EBITDA: $28.6m (down 8% year-over-year); Adjusted EBITDA: $63.0m, reflecting significant non-operating items.

• Adjusted operating cash flow from continuing operations: $16.9m (down 38% year-over-year).

• Cash and marketable securities at period end: $67.4m.

• Net loss from continuing operations: $12.1m (improved from $20.0m loss year-over-year).

Outlook and guidance

• Focus on market share growth in Women's Health, leveraging refreshed marketing and product access, and protecting IP.

• Dermatology to advance disintermediation strategy and expand into new therapeutic areas.

• International segment to unlock value from NEXTSTELLIS PBS listing, CapEx investments, and supply agreements.

• Continued investment in existing assets and product launches to support future revenue streams.